Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin

BMC Geriatrics

Table 5 Poor Health Status and Its Individual Components by Initial Second-Line Antidiabetic Medication Class

Health status variables^a	Total	SFU	BI	Other
Health status variables^a	N (%)	N (%)	N (%)	N (%)
Poor health^b
No	79,544 (94)	43,199 (94)	10,788 (89)	25,557 (95)
Yes	5,176 (6)	2,535 (6)	1,377 (11)	1,264 (5)
End-stage conditions^c
No	82,810 (98)	44,712 (98)	11,733 (96)	26,365 (98)
Yes	1,910 (2)	1,022 (2)	432 (4)	456 (2)
Dementia^d
No	82,391 (97)	44,597 (98)	11,579 (95)	26,215 (98)
Yes	2,329 (3)	1,137 (2)	586 (5)	606 (2)
Residence in nursing facility^e
No	82,631 (98)	44,860 (98)	11,414 (94)	26,357 (98)
Yes	2,089 (2)	874 (2)	751 (6)	464 (2)

BI basal insulin, SFU sulfonylurea
^a All participant characteristics listed were significantly associated with initial second-line antidiabetic medication class with a P-value of <0.001
^b Poor health was defined according to the following criteria modified from the 2019 Endocrine Society Guidelines for diabetes management in older adults: (1) end-stage conditions; (2) dementia; or (3) residence in a long-term nursing facility
^c End-stage conditions included in the 2019 Endocrine Society’s definition of poor health were: metastatic cancer, oxygen-dependent lung disease, chronic kidney disease stages IV or V, end-stage kidney disease, dialysis status, and advanced heart failure. Diagnostic codes used to define these conditions are listed in Table 2
^d Diagnosis codes used to define dementia are listed in Table 2
^e Residence in a long-term nursing facility was defined using Place of Service (POS) and CPT codes listed in Table 2

ISSN: 1471-2318